Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Mizuho Securities Maintains a Buy Rating on Sarepta Therapeutics (SRPT)
08:10am, Thursday, 30'th Apr 2020
Mizuho Securities analyst
Difei Yang
maintained a
Buy
rating on Sarepta Therapeutics (
SRPT
–
Research Report
) today and set a price target of
$183.00
. The company’s shares closed last Wednesday
Schmetterlinge anlocken - Schmetterlinge - Metamorphose und Futterpflanzen in Bildern
06:12am, Thursday, 30'th Apr 2020
Wir zeigen die vier Stadien der Verwandlung und welche Pflanzen Schmetterlinge anlocken und Raupen zum fressen brauchen.
Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline
12:00am, Thursday, 30'th Apr 2020
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets. Howard Robin, President and
Biodiversität auf dem Balkon - Artenreich, pflegeleicht, essbar? - Tipps für jeden Balkontypen
06:42am, Tuesday, 28'th Apr 2020
Egal ob Urban-Gardening-Freak oder Gärtner-Muffel - diese Tipps haben für jeden Balkonbesitzer etwas dabei.
Nektar Therapeutics (NASDAQ:NKTR) Earns Buy Rating from Analysts at Benchmark
08:52am, Saturday, 25'th Apr 2020
Benchmark started coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report sent to investors on Wednesday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a
Head to Head Survey: Eli Lilly And Co (NYSE:LLY) versus Syros Pharmaceuticals (NYSE:SYRS)
06:28am, Saturday, 25'th Apr 2020
Eli Lilly And Co (NYSE:LLY) and Syros Pharmaceuticals (NASDAQ:SYRS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their r
Outlook on the Worldwide Polymer-Drug Conjugate Industry to 2025 - by Manufacturers, Regions, Technology & Application
11:33am, Friday, 24'th Apr 2020
Dublin, April 24, 2020 -- The "Polymer-Drug Conjugate Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology,.
Sarepta Therapeutics (SRPT) Received its Third Buy in a Row
08:13am, Thursday, 23'rd Apr 2020
After Cowen & Co. and RBC Capital gave Sarepta Therapeutics (NASDAQ: SRPT) a Buy rating last month, the company received another Buy, this time from
Sarepta Therapeutics (SRPT) Received its Third Buy in a Row
08:13am, Thursday, 23'rd Apr 2020
After Cowen & Co. and RBC Capital gave Sarepta Therapeutics (NASDAQ: SRPT) a Buy rating last month, the company received
Mizuho Securities Thinks Xeris Pharmaceuticals' Stock is Going to Recover
08:11am, Thursday, 23'rd Apr 2020
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $14.00. The
Mizuho Securities Thinks Xeris Pharmaceuticals’ Stock is Going to Recover
08:11am, Thursday, 23'rd Apr 2020
In a report released today,
Difei Yang
from Mizuho Securities maintained a
Buy
rating on Xeris Pharmaceuticals (
XERS
–
Research Report
), with a price target of
$14.00
. The company’s shares clos
Global Polymer-Drug Conjugate Market (2020 to 2025) - Analysis and Forecast - ResearchAndMarkets.com
05:12pm, Wednesday, 22'nd Apr 2020
The "Polymer-Drug Conjugate Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarke
Benchmark Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target to $26
12:13pm, Wednesday, 22'nd Apr 2020Benchmark starts Nektar at Buy, has conviction in bempeg's odds in melanoma NKTR
11:46am, Wednesday, 22'nd Apr 2020
Benchmark starts Nektar at Buy, has conviction in bempeg's odds in melanoma Benchmark NKTR
